In the current venture capital climate, the term "AI-first" has become the industry’s most potent—and most misunderstood—buzzword. Founders are scrambling to brand their startups as "AI-native," investors are pouring billions into anything with a generative interface, and buyers are struggling to distinguish between transformative technology and ephemeral "AI-washing."
But as the dust settles on 2025, a critical realization is dawning on the healthcare sector: being "AI-first" is not a business strategy; it is a tactical choice. The real battle for market dominance isn’t being fought over who has the most impressive model, but rather who owns the workflow, the data, and the trust of the end user.
The Market Landscape: A Capital-Rich, Strategy-Poor Environment
The financial data from 2025 paints a picture of a sector obsessed with intelligent automation. According to Rock Health, AI-enabled companies commanded a staggering 54% of all digital health funding in 2025. This wasn’t just speculative capital; it was driven by genuine, albeit frantic, demand from healthcare organizations.
KLAS Research reports that the adoption of AI within healthcare systems surged, moving from less than 50% of surveyed organizations at the start of the year to over two-thirds by year’s end. This reflects a "must-have" mentality among providers, who are increasingly fearful of being left behind by the technology curve.
However, beneath the surface of this massive capital injection lies a fundamental tension: founders are caught between building something durable—a company that will be around in ten years—and building something timely, designed to catch the current wave of investment before the hype cycle shifts.
Chronology: The Evolution of "Tech-First" Disruptions
To understand why the market is currently rewarding AI "bluster," we must look at the history of digital transformation. We have seen this movie before, with mobile-first and web3.
- 2010–2015 (The Mobile-First Wave): Startups like DrChrono positioned themselves as the "mobile-friendly EHR." They gained rapid market share by solving the specific pain point of portability.
- 2015–2018 (The Defensive Response): Legacy EHR giants recognized the threat, cannibalized those differentiators, and integrated mobile capabilities into their monolithic platforms. The startups were either acquired or relegated to niche segments.
- 2020–2023 (The Web3/Blockchain Hype): A surge of interest in decentralized health records and ledger-based claims occurred, most of which failed to achieve mass adoption because they lacked the necessary "workflow gravity."
- 2024–2025 (The AI-First Era): We are currently in the peak of the AI hype cycle. Just as mobile-first was a feature, not a business model, AI is a tool—a sophisticated Swiss Army knife—not an end state.
The lesson from history is clear: The differentiator is never the tech; the differentiator is the workflow.
Supporting Data: Where AI Actually Sticks
While the media focuses on the flashiest generative AI tools, the data reveals that healthcare enterprises are much more pragmatic. KLAS Research indicates that the highest adoption rates for AI occur in "well-defined" areas where the ROI is immediate and the risk is manageable:
- Revenue Cycle Automation: Using AI to speed up claims submission and coding.
- Transcription and Documentation: Reducing the administrative burden on clinicians.
- Administrative Triage: Automating scheduling and patient communication.
These are not "agentic" breakthroughs that act autonomously; they are precision tools designed to solve specific operational bottlenecks. Healthcare leaders are not buying "AI"; they are buying efficiency, and they are doing so with a very picky palate.
Two Categories: The Divergent Paths of Survival
In the current market, companies are splitting into two distinct categories, each facing a unique existential threat.
1. The AI-Native Startups
These firms were born out of the large language model (LLM) boom. Their advantage is speed and a lack of legacy technical debt. However, their primary risk is "Feature-fication." If their entire value proposition is a wrapper around a foundation model, they are merely a feature waiting to be integrated into a larger, established platform. To survive, they must move beyond the "novelty" phase and build proprietary moats—either through unique, defensible datasets or deep integration into complex, high-friction workflows.
2. The Legacy Software Companies (Vertical SaaS)
These companies own the "system of record." They sit in the middle of their clients’ daily lives. Their risk is "Irrelevance." If they move too slowly, a nimbler competitor will displace them. However, they have a massive head start: they already have the customers, the data, and the workflow control. Their task is not to become "AI-native," but to use AI to reinforce their existing moats, making themselves even harder to replace.
Implications: The Death of the Point Solution
The market is currently experiencing "point solution fatigue." CIOs and healthcare executives are tired of managing a sprawling stack of niche AI tools that don’t talk to each other. This creates a closing window for startups that provide only a single, narrow AI function.
If a company does not control the system—if they don’t own the relationship, the data, and the workflow—their ability to prove ROI consistently will evaporate. As the novelty of generative AI fades, healthcare buyers will shift their focus back to fundamental business metrics:
- Retention: Are users staying because of the AI, or are they staying because the tool is vital to their workflow?
- Domain Control: Does the company understand the nuances of healthcare regulation, billing, and clinical practice, or are they just a generic tool applied to a specific problem?
- Integration: Is the AI tool a "pain" to remove, or is it a "nice-to-have" add-on?
Conclusion: The Path Forward for Founders
For those building in the healthcare space, the path forward is actually quite traditional. The job hasn’t changed; the tools have just become more powerful.
The companies that will win over the next decade are not the ones shouting "AI-first" the loudest. They are the ones that use AI to solve the most painful, boring, and complex parts of a workflow. If your AI is merely a "screwdriver," you are replaceable. If your AI helps you become the "DeWalt" of your category—a tool that is trusted, reliable, and integrated into every aspect of the job—you have built a durable company.
AI will eventually become "ordinary." It will be an underlying utility, much like cloud computing or mobile accessibility. The obsession with being "AI-native" will pass, replaced by a focus on "AI-enabled" businesses that actually provide value. For founders, the best advice is to stop worrying about the label and start worrying about the moat. If you control the workflow, you control your destiny.
As we look toward the remainder of the decade, the winners will be the companies that treat AI as a means to an end—the end being a more efficient, sustainable, and integrated healthcare system. The confusion in the market is real, but it is also a filter. It is separating those who are playing the game of "AI bluster" from those who are playing the game of building real, defensible value. In the end, the market will reward the latter.
